Stemline Therapeutics Announces Positive Clinical Data from ELZONRISTM (tagraxofusp; SL-401) Trials in BPDCN, CMML and MF Delivered at the EHA Congress |…
NEW YORK, June 18, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that positive clinical data from ELZONRISTM (tagraxofusp; SL-401) trials were presented at the 23rdCongress of the European Hematology Association (EHA) in Stockholm, Sweden.